A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
Status:
Unknown status
Trial end date:
2019-10-25
Target enrollment:
Participant gender:
Summary
WXFL10030390 (WX390) is a novel oral small molecular that inhibits phosphoinositide-3 kinase
(PI3K) and mammalian target of rapamycin (mTOR) and has demonstrated potent inhibitory
effects on multiple human tumor xenografts. The first-in-human study is conducted to assess
the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the
pharmacokinetics, safety and preliminary anti-tumor activity of WX390 at single dose and
multiple doses.